Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Compare leukemia-free survival

Compare leukemia-free survival at five years from DIPSS assessment date to the date of progression to AML or death from any cause, whichever comes first. Two co-secondary analyses will be conducted, one for all alloHCT patients versus Arm 2 and one for the subset of patients receiving MAC prior to alloHCT versus Arm 2. Observation is censored at the date of last follow-up for patients known to be alive without leukemia. Progression to AML is defined as \>20% leukemia blasts in bone marrow or in the peripheral blood.

Time frame: Five years post transplant

Cumulative incidences of chronic GVHD

Occurrence of symptoms in any organ system fulfilling the criteria of chronic GVHD. Patients are censored at last follow-up or second transplant.

Time frame: Five years post transplant

Cumulative incidences of acute GVHD

Occurrence of grade II, III, and/or IV skin, gastrointestinal, or liver abnormalities fulfilling the Consensus criteria of acute GVHD. Patients are censored at last follow-up or second transplant.

Time frame: Five years post transplant

Cumulative incidence of treatment related mortality

Death from any cause in the first 28 days post-transplantation, irrespective of relapse status. Death beyond day +28 will only be considered transplant-related if the disease is in remission. This event will be summarized as a cumulative incidence estimate with relapse/persistence as the competing risk.

Time frame: Five years post transplant

The impact of certain patient, disease and HCT related factors on survival in the alloHCT arm.

Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 years vs. \>= 65 years, disease duration and DIPSS on overall survival in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

Time frame: Five years post transplant

The impact of certain patient, disease and HCT related factors on leukemia free survival in the alloHCT arm.

Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs. \>= 65 years), disease duration and DIPSS on leukemia free survival in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

Time frame: Five years post transplant

The impact of certain patient, disease and HCT related factors on hematopoietic recovery in the alloHCT arm.

Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs \>=65 years), disease duration and DIPSS on hematopoietic recovery in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

Time frame: Five years post transplant

The impact of certain patient, disease and HCT related factors on acute and chronic GVHD in the alloHCT arm.

Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs \>= 65 years), disease duration and DIPSS on acute and chronic GVHD in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

Time frame: Five years post transplant

The impact of certain patient, disease and HCT related factors on treatment related mortality in the alloHCT arm.

Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs \>=65 years), disease duration, and DIPSS on treatment related mortality in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

Time frame: Five years post transplant.

The impact of certain patient, disease and HCT related factors on relapse.

Evaluation of the impact of response to ruxolitinib therapy, patient age (65 vs \>=65 years), disease duration and DIPSS on relapse in the alloHCT arm. The time to event in the analyses will start at the time of transplant.

Time frame: Five years post transplant.